Abstract:366 Background: There is a paucity of data with respect to optimal management of metastatic renal cell carcinoma (mRCC) in older adults. Real world data may help close this knowledge gap and improve care for older patients with mRCC. Methods: The Canadian Kidney Cancer information system (CKCis) was utilized to identify patients with mRCC, categorizing them as either older (defined as age ≥75 years) or younger (age <75 years). We compared first line (1L) mRCC management strategies and treatment-related toxicities. Secondary outcomes were overall survival (OS) and time to treatment discontinuation (TTD). Chi-Square and Fisher’s Exact tests were used to compare groups, and survival outcomes were measured by Kaplan-Meier method. Cox’s proportional hazard ratio (HR) were reported by age adjusting for IMDC risk groups, histology, and Charlson Comorbidity Index (CCI) for OS and TTD. Results: 2576 patients were included (n=2203 <75 years old; n=373 ≥75 years old). Baseline demographics were comparable between groups, though older patients had more comorbidities (5+, 95% vs. 67%, p<0.0001) and more frequently had Karnofsky Performance Status <70% (18% vs. 13%, p=0.01). Older patients underwent metastasectomy less frequently (15% vs. 25%, p=0.0001) and were less likely to be enrolled in clinical trials (10% vs. 24%, p<0.0001). Older patients received 1L tyrosine kinase inhibitor (TKI) monotherapy more frequently (79% vs. 69%, p<0.0001) than immune checkpoint inhibitor (ICI)-based treatment, even when adjusted by year to account for changes in practice patterns in the post-ICI era (65% vs. 44%, p<0.0001). Amongst all patients, the TKI monotherapy most frequently prescribed was sunitinib, though older patients were more likely to receive pazopanib than younger patients ( p<0.0001). Amongst all patients who received 1L ICI-based treatment, there was no difference in the type of ICI regimen (i.e. doublet ICI versus ICI plus TKI) prescribed when compared by age ( p=0.61). Older patients did not experience more frequent treatment-related toxicities with ICI-based treatment. They did however experience more grade 3+ toxicity with TKI monotherapy. Older patients had shorter OS even when controlling for IMDC score, CCI and histology (HR 1.21, 95% CI 1.03-1.43, p=0.02). There was no difference in TTD by groups. Conclusions: Patients ≥75 years of age received TKI monotherapy more frequently than those <75 years of age, though when they received ICI-based regimens, they did not experience more treatment-related toxicities nor more dose modifications. Clinicians should individualize treatments for older patients not solely based on age, but after discussion of all available options in a patient-centered manner, considering comorbidities, disease burden, and patient preferences.

Special populations in metastatic renal cell carcinoma

Metastatic Melanoma Treatment in Special Populations

Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations

Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).

Metastatic Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patient: A Systematic Review

Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations.

Recent Advances in Single-Cell RNA-Sequencing of Primary and Metastatic Clear Cell Renal Cell Carcinoma

Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review

Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

Treatment options and outcome of patients with metastatic renal cell carcinoma with brain or bone metastases: Real world evidence from a German retrospective multi-center analysis.

How To Deal With Renal Toxicities From Immune-Based Combination Treatments In Metastatic Renal Cell Carcinoma. A Nephrological Consultation For Oncologists

Biology of metastatic renal cell carcinoma

Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review

Surgical metastasectomy for metastatic renal cell carcinoma in the era of targeted and immune therapy: a narrative review

An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma

Frailty and Renal Cell Carcinoma: Integration of Comprehensive Geriatric Assessment into Shared Decision-making

New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunities

A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma

Definitions and unmet needs in the management of oligomestatic renal cell carcinoma in the modern era

A Scoping Review of Population Diversity in the Common Genomic Aberrations of Clear Cell Renal Cell Carcinoma